Table 2.

Treatment-related adverse events (AEs)

	Grade 1–2	Grade 3	Grade 4	Grade 5
Any treatment-related AE	58 (96.7%)	34 (56.7%)	4 (6.7%)	1 (1.7%)
Leukocytopenia	22 (36.7%)	26 (43.3%)	4 (6.7%)	0
Thrombocytopenia	31 (51.7%)	4 (6.7%)	0	0
Anemia	47 (78.3%)	3 (5.0%)	1 (1.7%)	0
Increased AST/ALT	23 (38.3%)	2 (3.3%)	0	0
Increased γ-GT	9 (15.0%)	0	0	0
Increased LDH/AKP	37 (61.7%)	0	0	0
Nausea	10 (16.7%)	0	0	0
Vomiting	5 (8.3%)	0	0	0
Diarrhea	4 (6.7%)	0	0	0
Constipation	6 (10.0%)	0	0	0
Asthenia or fatigue	18 (30.0%)	0	0	0
Fever	6 (10.0%)	2 (3.3%)	0	0
Alopecia	42 (70.0%)	0	0	0
Blurred vision	3 (5.0%)	1 (1.7%)	0	0
Neurotoxicity	3 (5.0%)	0	0	0
Proteinuria	5 (8.3%)	0	0	0
Urinary infection	2 (3.3%)	0	0	0
Cutaneous capillary proliferation	16 (26.7%)	0	0	0
Rash maculopapular	10 (16.7%)	0	0	0
Pruritus	10 (16.7%)	0	0	0
Pneumonia	1 (1.7%)	2 (3.3%)	0	1 (1.7%)
Hypothyroidism	4 (6.7%)	0	0	0
Hyperthyroidism	1 (1.7%)	0	0	0

AKP, alkline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; GT, glutamyltranspeptidase; LDH, lactate dehydrogenase.